1940-44-9

Basic information

• Product Name: 4-BROMO-2,3-DICHLOROPHENOL
• Synonyms: 4-BROMO-2,3-DICHLOROPHENOL
• CAS NO: 1940-44-9
• Molecular Formula: C₆H₃BrCl₂O
• Molecular Weight: 241.9
• Mol File: 1940-44-9.mol
• Article Data: 12

Chemical Properties

• Melting Point: 53-54 °C
• Boiling Point: 277.3±35.0 °C(Predicted)
• Appearance: /
• Density: 1.890±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 6.98±0.23(Predicted)
• CAS DataBase Reference: 4-BROMO-2,3-DICHLOROPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2,3-DICHLOROPHENOL(1940-44-9)
• EPA Substance Registry System: 4-BROMO-2,3-DICHLOROPHENOL(1940-44-9)

Safety Data

• Hazardous Substances Data: 1940-44-9(Hazardous Substances Data)

Usage

Description

4-Bromo-2,3-dichlorophenol is a halogenated phenol chemical compound characterized by the presence of a bromine atom at the 4-position and two chlorine atoms at the 2 and 3 positions on the phenol ring. It is known for its antimicrobial properties and is utilized as an intermediate in the synthesis of various organic compounds, including pharmaceuticals and agrochemicals.

Uses

Used in Pharmaceutical Synthesis:
4-Bromo-2,3-dichlorophenol is used as an intermediate in the synthesis of pharmaceuticals for its ability to be chemically modified to produce a range of medicinal compounds.
Used in Agrochemical Production:
In the agrochemical industry, 4-Bromo-2,3-dichlorophenol serves as a precursor in the production of various agrochemicals, contributing to the development of pesticides and other agricultural products.
Used as a Disinfectant in Industrial and Healthcare Settings:
Leveraging its antimicrobial properties, 4-Bromo-2,3-dichlorophenol is utilized as a disinfectant in a variety of settings, including industrial processes and healthcare facilities, to ensure cleanliness and prevent the spread of infections.
Used in the Synthesis of Dyes and Pigments:
4-BROMO-2,3-DICHLOROPHENOL is also employed in the synthesis of dyes and pigments, where its chemical structure contributes to the color and properties of the final products.
However, it is important to note that 4-Bromo-2,3-dichlorophenol is considered potentially harmful to human health and the environment. Therefore, strict precautions should be taken during its handling and use to minimize any adverse effects.

Upstream product

• 576-24-9 2,3-dichlorophenol 

Downstream Products

• 207238-25-3 3-benzyloxy-4-bromo-1,2-dichlorobenzene 
• 515846-27-2 (4-bromo-2,3-dichloro-phenoxy)-triisopropyl-silane 
• 109803-52-3 1-bromo-2,3-dichloro-4-methoxybenzene 
• 55901-80-9 2,3-dichloro-4-methoxy-benzoic acid 
• 76238-31-8 2,3-dichloro-4-methoxybenzoyl chloride 
• 515846-31-8 2,3-dichloro-4-triisopropylsilanyloxy-benzoyl chloride 
• 515846-30-7 2,3-dichloro-4-triisopropylsilanyloxy-benzoic acid 
• 515846-36-3 (R)-[1-(2-{4-[5-(2,3-dichloro-4-hydroxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 515846-52-3 (R)-[1-(2-{4-[5-(2,3-dichloro-4-methoxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 515846-33-0 (R)-[1-(2-{4-[3-(2,3-dichloro-4-triisopropylsilanyloxy-phenyl)-3-oxo-prop-1-ynyl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 515846-35-2 (R)-[1-(2-{4-[5-(2,3-dichloro-4-triisopropylsilanyloxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 515846-39-6 (R)-5-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]furan-2-carboxylic acid methyl ester 
• 515846-48-7 (R)-3-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]benzoic acid 
• 515846-59-0 (R)-4-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]benzoic acid 

Relevant articles and documents

TARGETED BIFUNCTIONAL DEGRADERS

The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS

The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, FcyRI, FcRN, Transferrin or Macrophage Scavenger receptor. Pharmaceutical compositions based upon these bifunctional small molecules represent an additional aspect of the present invention. These compounds and/or compositions may be used to treat disease states and conditions by removing circulating proteins through degradation in the hepatocytes or macrophages of a patient or subject in need of therapy. Methods of treating disease states and/or conditions in which circulating proteins are associated with the disease state and/or condition are also described herein.

NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.